Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Telix Pharmaceuticals ( (AU:TLX) ) is now available.
Telix Pharmaceuticals Limited has announced the cessation of 135,000 share rights under the ASX security code TLXAP, effective May 16, 2025. This announcement may impact the company’s capital structure and could have implications for its stakeholders, as it reflects changes in the company’s issued securities.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$19.30 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development and commercialization of diagnostic and therapeutic products using molecularly targeted radiation (MTR). The company aims to address significant unmet medical needs in oncology and rare diseases, leveraging its expertise in radiopharmaceuticals to enhance patient care.
Average Trading Volume: 1,968,807
Technical Sentiment Signal: Buy
Current Market Cap: A$8.64B
See more data about TLX stock on TipRanks’ Stock Analysis page.